Bildkälla: Stockfoto

Cantargia Q1 2024: Notable Cost Reductions - Redeye

Redeye comments on Cantargia's Q1 report. The main thing that stands out is the great Q/Q cost reduction. There has also been developments in inflammatory diseases relevant for CAN10.

Redeye comments on Cantargia's Q1 report. The main thing that stands out is the great Q/Q cost reduction. There has also been developments in inflammatory diseases relevant for CAN10.
Börsvärldens nyhetsbrev
ANNONSER